1-3 of 3
Jeff Haessler, MD
Close
Sort by
Journal Articles

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

Herve Avet-Loiseau, Brian G M Durie, Jeff Haessler, MD, John Crowley, PhD, Antje Hoering, Ph.D., Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., Orhan Sezer, Chaim Shustik, MD, Roman Hajek, MD, Harmut Goldschmidt, Pieter Sonneveld, Philippe Moreau, MD, Michel Attal, MD, Antonio Palumbo, M.D., Mario Boccadoro, MD, Jae Hoon Lee, Jan Westin, MD, PhD, Ingemar Turesson, MD, PhD, Jesús F. San Miguel, Joan Blade, Juan José Lahuerta, MD, PhD, Santiago Pavlovsky, MD, PhD, Dorotea Beatriz Fantl, MD, S.Vincent Rajkumar, M.D., Rafael Fonseca, MD
Journal: Blood
Blood (2009) 114 (22): 743.
https://doi.org/10.1182/blood.V114.22.743.743
Published: 2009
Journal Articles

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Michele H. Cottler-Fox, MD, Jeff Haessler, MD, Sarah Waheed, MD, Bijay Nair, MD, John Crowley, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3411.
https://doi.org/10.1182/blood.V114.22.3411.3411
Published: 2009
Journal Articles

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Bart Barlogie, MD, PhD, Elias J. Anaissie, MD, John D. Shaughnessy, Jr., PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Jeff Haessler, MD, Klaus A. Hollmig, MD, Yazan Alsayed, MD, Sarah Waheed, MD, Monica Graziutti, MD, Elias Kiwan, MD, John Crowley, PhD
Journal: Blood
Blood (2008) 112 (11): 162.
https://doi.org/10.1182/blood.V112.11.162.162
Published: 2008